CSF3 and neutropenia: In a large-scale EORTC trial, dose levels of ifosfamide 5 g m−2 and doxorubicin 50 mg m−2 but without G-CSF led also to severe neutropenia in 86%, and thrombopenia in 8% of patients (Le Cesne et al, 2000).